Colitis could occur at any time after the commencement of ICIs, with an earlier occurrence with PD-1 inhibitors [24], but a greater severity with anti-CTLA-4 and, especially, with combination therapy [12,15,23,25]. The gene discussed is CTLA4; the disease is colitis.